{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:09:01Z","timestamp":1781651341263,"version":"3.54.5"},"reference-count":10,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T00:00:00Z","timestamp":1582761600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>Ranitidine has been the topic of recent media reports. Current findings, confirmed by the US Food and Drug Administration, indicate that some ranitidine products contain a substance that may be carcinogenic. Providers and patients require additional information on the risks of continuing therapy vs. the benefits of the medication. This article comments on what is currently known about the evolving situation of elevated N\u2010nitrosodimethylamine levels in ranitidine and the limits of the existing information to assess best practices.<\/jats:p>","DOI":"10.1111\/cts.12753","type":"journal-article","created":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T12:20:46Z","timestamp":1582892446000},"page":"649-651","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Medicine and Media: The Ranitidine Debate"],"prefix":"10.1111","volume":"13","author":[{"given":"Jennifer A.","family":"Wagner","sequence":"first","affiliation":[{"name":"Children\u2019s Mercy Hospital Kansas City Missouri USA"},{"name":"University of Missouri\u2010Kansas City School of Medicine Kansas City Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Colombo","sequence":"additional","affiliation":[{"name":"Children\u2019s Mercy Hospital Kansas City Missouri USA"},{"name":"University of Missouri\u2010Kansas City School of Medicine Kansas City Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,2,27]]},"reference":[{"key":"e_1_2_4_1_1","unstructured":"Light D.&Kucera K. Re.Valisure citizen petition on rantidine. Valisure LLC <https:\/\/www.valisure.com\/wp-content\/uploads\/Valisure-Ranitidine-FDA-Citizen-Petition-v4.12.pdf> (2019). Accessed November 26 2019."},{"key":"e_1_2_4_2_1","unstructured":"Woodcock J.Statement on new testing results including low levels of impurities in ranitidine drugs. FDA Statement <https:\/\/www.fda.gov\/news-events\/press-announcements\/statement-new-testing-results-including-low-levels-impurities-ranitidine-drugs> (2019). Accessed November 22 2019."},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2012.53.6.1154"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2003.08.005"},{"key":"e_1_2_4_5_1","first-page":"1","article-title":"Overall evaluations of carcinogenicity: an updating of IARC monographs volumes 1\u201342","volume":"7","author":"IARC (International Agency for Research on Cancer)","year":"1987","journal-title":"IARC Monogr. Eval. Carcinog. Risks Hum. Suppl."},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0007114513003462"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.12070"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.444"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/4.10.1281"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgw034"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcts.12753","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12753","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.12753","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T08:37:11Z","timestamp":1693903031000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.12753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,27]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1111\/cts.12753"],"URL":"https:\/\/doi.org\/10.1111\/cts.12753","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,27]]},"assertion":[{"value":"2019-12-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}